Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Can cetuximab affect paraneoplastic myopathy?

Galani E, Bonakis A, Christodoulou C, Klouvas G, Drougou A, Skarlos D.

J Neurooncol. 2009 Jul;93(3):437-8. doi: 10.1007/s11060-009-9795-6. Epub 2009 Jan 22. Erratum in: J Neurooncol. 2009 Jul;93(3):439. Angeliki, Drougou [corrected to Drougou, Angeliki].

PMID:
19159079
2.

Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer.

Geurs F, Vandewaeter S, Ponette S, Ponette J, Knape S, Demetter P.

J Gastrointest Cancer. 2008;39(1-4):26-8. doi: 10.1007/s12029-009-9060-4. Epub 2009 May 6. No abstract available.

PMID:
19418267
3.

[Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].

Guo GF, Xia LP, Qiu HJ, Xu RH, Zhang B, Jiang WQ, Zhou FF, Wang F.

Zhonghua Zhong Liu Za Zhi. 2010 Oct;32(10):777-81. Chinese.

PMID:
21163071
4.

Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report.

Toyama Y, Ushigome T, Watanabe K, Kitamura H, Onda S, Saito R, Yoshida S, Kawahara H, Yanagisawa S, Yanaga K.

World J Surg Oncol. 2012 Jun 29;10:129. doi: 10.1186/1477-7819-10-129.

5.

Epidermal growth factor receptor inhibition induces trichomegaly.

Dueland S, Sauer T, Lund-Johansen F, Ostenstad B, Tveit KM.

Acta Oncol. 2003;42(4):345-6. No abstract available.

PMID:
12899508
6.

[A review of chemotherapy for metastatic colon cancer].

Díez-Fernández R, Salinas Hernández P, Girón-Duch C.

Farm Hosp. 2006 Nov-Dec;30(6):359-69. Review. Spanish.

7.

Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.

Larsen FO, Pfeiffer P, Nielsen D, Skougaard K, Qvortrup C, Vistisen K, Fromm AL, Jørgensen TL, Bjerregaard JK, Hoegdall E, Jensen BV.

Acta Oncol. 2011 May;50(4):574-7. doi: 10.3109/0284186X.2010.546369.

PMID:
21529301
8.

[Cetuximab improved the poor performance status of a colorectal cancer patient].

Sakisaka H, Kato T, Kagawa Y, Ishida T, Sato Y, Morimoto Y, Matsushita K, Hashimoto T, Kusama H, Kimura K, Katsura Y, Nitta K, Okishiro M, Takeno A, Nakahira S, Taniguchi H, Egawa C, Takeda Y, Tamura S.

Gan To Kagaku Ryoho. 2014 Nov;41(12):1776-8. Japanese.

PMID:
25731326
9.

Current stages of adjuvant treatment of colon cancer.

Köhne CH.

Ann Oncol. 2012 Sep;23 Suppl 10:x71-6. No abstract available.

PMID:
22987996
10.

Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.

Asseburg C, Frank M, Köhne CH, Hartmann JT, Griebsch I, Mohr A, Osowski U, Schulten J, Mittendorf T.

Clin Ther. 2011 Apr;33(4):482-97. doi: 10.1016/j.clinthera.2011.04.010.

PMID:
21635994
11.

Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: superior progression-free survival is restricted to patients with measurable tumors and objective tumor response--a retrospective study.

Yang YH, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, Lan YT, Lin CC, Yen CC, Tzeng CH, Teng HW.

J Cancer Res Clin Oncol. 2014 Nov;140(11):1927-36. doi: 10.1007/s00432-014-1741-0. Epub 2014 Jun 17.

PMID:
24934725
12.

[Follicular drug reaction from cetuximab: a common side effect in the treatment of metastatic colon carcinoma].

Braun-Falco M, Holtmann C, Lordick F, Ring J.

Hautarzt. 2006 Aug;57(8):701-4. German.

PMID:
15991047
13.

Liver resection after FOLFOX with bevacizumab.

Mickle M, Mulcahy MF.

Clin Adv Hematol Oncol. 2007 Jan;5(1 Suppl 1):12-4. No abstract available.

PMID:
17491587
14.

[A case of multiple lung and liver metastases from colon cancer treated with clinical benefit by hepatic arterial infusion chemotherapy plus cetuximab mono-therapy after standard chemotherapy failure].

Osawa G, Yoshimatsu K, Yokomizo H, Otani T, Yano Y, Itagaki H, Matsumoto A, Fujimoto T, Umehara A, Ogawa K.

Gan To Kagaku Ryoho. 2010 Nov;37(12):2526-8. Japanese.

PMID:
21224628
15.

[Efficacy of cetuximab combined with chemotherapy on advanced colorectal cancer: a report of 53 cases].

Guo GF, Xia LP, Zhang B, Jiang WQ, Liu MZ, Hu PL, Chen XX, Qiu HJ, Zhou FF.

Ai Zheng. 2009 Dec;28(12):1317-23. Chinese.

PMID:
19958628
16.

Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer.

Halama N, Herrmann C, Jaeger D, Herrmann T.

Anticancer Res. 2008 Nov-Dec;28(6B):4111-5.

17.

[A surgical (right lobectomy) case of liver metastasis of colon cancer after chemotherapy using mFOLFIRI and cetuximab].

Shimobayashi T, Inatsugi N, Yoshikawa S, Masuda T, Uchida H, Kuge H, Yokotani T, Yamaguchi T, Kawaguchi C, Yamaoka K, Inagaki M, Matsuoka M, Tatsumi K, Saraya T, Otsuji T, Yamochi Y, Yamanishi K, Enomoto Y, Nonomura A, Sho M, Nakajima Y.

Gan To Kagaku Ryoho. 2010 Nov;37(12):2340-2. Japanese.

PMID:
21224566
18.

Maintenance therapy in colon cancer.

Giuliani F, De Vita F, Colucci G, Pisconti S.

Cancer Treat Rev. 2010 Nov;36 Suppl 3:S42-5. doi: 10.1016/S0305-7372(10)70019-0. Review.

PMID:
21129609
19.

Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.

Fornaro L, Vasile E, Masi G, Loupakis F, Baldi GG, Allegrini G, Salvatore L, Cremolini C, Cupini S, Cortesi E, Tuzi A, Granetto C, Brunetti IM, Ricci S, Falcone A.

Clin Colorectal Cancer. 2012 Mar;11(1):71-6. doi: 10.1016/j.clcc.2011.06.013. Epub 2011 Sep 8.

PMID:
21903485
20.

Two new drugs for colon cancer.

[No authors listed]

Med Lett Drugs Ther. 2004 Jun 7;46(1184):46-8. No abstract available.

PMID:
15184808

Supplemental Content

Support Center